Compare TECH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | RLAY |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 1.4B |
| IPO Year | 1989 | 2020 |
| Metric | TECH | RLAY |
|---|---|---|
| Price | $59.42 | $8.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $71.23 | $16.00 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $1,216,732,000.00 | $8,355,000.00 |
| Revenue This Year | $2.33 | $20.47 |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | $121.73 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $46.01 | $1.78 |
| 52 Week High | $79.28 | $9.04 |
| Indicator | TECH | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 63.83 |
| Support Level | $56.84 | $8.13 |
| Resistance Level | $59.58 | $8.81 |
| Average True Range (ATR) | 1.86 | 0.51 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 35.21 | 75.93 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).